Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase EARLY_PHASE1 1 Phase 4 1 Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 8 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cisplatin 294 Radiotherapy 230 Fluorouracil 201 Cyclophosphamide 191 Capecitabine 183 Docetaxel 167 Gemcitabine 165 Oxaliplatin 162 Carboplatin 161 Paclitaxel 152 Leucovorin 122 Drug Therapy 119 Dexamethasone 119 Doxorubicin 112 Etoposide 99 Bevacizumab 91 Cytarabine 87 Vincristine 83 Irinotecan 81 Rituximab 77 Epirubicin 71 Prednisone 65 Radiosurgery 63 Methotrexate 62 Surgical Procedures, Operative 61 Radiation 60 Radiotherapy, Intensity-Modulated 57 Neoadjuvant Therapy 53 Lenalidomide 52 Letrozole 51

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × OTHER × tofacitinib × Clear all

NCT05326464 2025-12-15

Tofacitinib in Recurrent GBM Patients

University of Texas Southwestern Medical Center

Phase 3 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡